Abstract:Background: Cluster randomized trials (CRTs) are randomized trials where randomization takes place at an administrative level (e.g., hospitals, clinics, or schools) rather than at the individual level. When the number of available clusters is small, researchers may not be able to rely on simple randomization to achieve balance on cluster-level covariates across treatment conditions. If these cluster-level covariates are predictive of the outcome, covariate imbalance may distort treatment effects, threaten internal validity, lead to a loss of power, and increase the variability of treatment effects. Covariate-constrained randomization (CR) is a randomization strategy designed to reduce the risk of imbalance in cluster-level covariates when performing a CRT. Existing methods for CR have been developed and evaluated for two- and multi-arm CRTs but not for factorial CRTs. Methods: Motivated by the BEGIN study-a CRT for weight loss among patients with pre-diabetes-we develop methods for performing CR in 2 × 2 factorial cluster randomized trials with a continuous outcome and continuous cluster-level covariates. We apply our methods to the BEGIN study and use simulation to assess the performance of CR versus simple randomization for estimating treatment effects by varying the number of clusters, the degree to which clusters are associated with the outcome, the distribution of cluster level covariates, the size of the constrained randomization space, and analysis strategies. Results: Compared to simple randomization of clusters, CR in the factorial setting is effective at achieving balance across cluster-level covariates between treatment conditions and provides more precise inferences. When cluster-level covariates are included in the analyses model, CR also results in greater power to detect treatment effects, but power is low compared to unadjusted analyses when the number of clusters is small. Conclusions: CR should be used instead of simple randomization when performing factorial CRTs to avoid highly imbalanced designs and to obtain more precise inferences. Except when there are a small number of clusters, cluster-level covariates should be included in the analysis model to increase power and maintain coverage and type 1 error rates at their nominal levels.

Including variants on randomized trials

[Risk Related to Bias Assessment: (4) Revised Cochrane Risk of Bias Tool for Cluster-Randomized Control Trials (Rob2.0)].

Subgroup identification in clinical trials: an overview of available methods and their implementations with R

Bias Risk Assessment: (3) Revised Cochrane Bias Risk Assessment Tool for Individual Randomized,cross-over Trials (Rob2.0)

RoB 2: a revised tool for assessing risk of bias in randomised trials

Intent-to-treat Analysis of Cluster Randomized Trials when Clusters Report Unidentifiable Outcome Proportions.

Extending inferences from a randomized trial to a new target population

Reference-trial-informed design to explore treatment effects in trial-underrepresented subgroups

[Risk on Bias Assessment: (2) Revised Cochrane Risk of Bias Tool for Individually Randomized, Parallel Group Trials (Rob2.0)].

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

Cluster Randomized Trials with a Pretest and Posttest: Equivalence of Three-, Two- and One-Level Analyses, and Sample Size Calculation

New designs for Bayesian adaptive cluster-randomized trials

Adaptive Clinical Trials: Exploiting Sequential Patient Recruitment and Allocation

A Utility-Based Design for Randomized Comparative Trials with Ordinal Outcomes and Prognostic Subgroups

Covariate-constrained randomization in cluster randomized 2 × 2 factorial trials: application to a diabetes prevention study

Comparing cluster-level dynamic treatment regimens using sequential, multiple assignment, randomized trials: Regression estimation and sample size considerations

Comparison of tests for categorical data from a stratified cluster randomized trial

Practical considerations in utilizing cluster randomized controlled trials conducted in biopharmaceutical industry

Extending inferences from a cluster randomized trial to a target population

Using Power Analysis to Choose the Unit of Randomization, Outcome, and Approach for Subgroup Analysis for a Multilevel Randomized Controlled Clinical Trial to Reduce Disparities in Cardiovascular Health